Fennec Pharmaceuticals Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies to prevent platinum-induced ototoxicity, primarily in pediatric cancer patients. The company’s main product is PEDMARK (sodium thiosulfate injection), an FDA-approved, ready-to-use intravenous formulation designed to reduce the risk of hearing loss associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. PEDMARK is marketed in the United States through regional pediatric oncology specialists and medical science liaisons and is also authorized for use under the brand name PEDMARQSI in Europe, the United Kingdom, Australia, and New Zealand. The company supports access to its product through specialized programs such as Fennec HEARS, a patient support initiative, and collaborates with oncology practices including large national oncology groups. Fennec Pharmaceuticals operates primarily in the biotechnology and healthcare sector, targeting pediatric oncology and cancer patient care markets. It conducts its operations mainly in North America and Europe, with ongoing development and commercialization efforts expanding into Japan. The company was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. Recent major developments include positive topline results from an investigator-initiated Phase 2/3 clinical trial of PEDMARK in Japan, demonstrating significant reduction in cisplatin-induced hearing loss without interfering with the chemotherapy’s antitumor activity. Based on these results, Fennec plans to pursue regulatory registration and explore partnering or licensing opportunities in Japan. In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand. PEDMARK has received multiple regulatory approvals and exclusivities including FDA approval in September 2022, European Commission approval in June 2023, U.K. approval in October 2023, Orphan Drug Exclusivity in the U.S., and Pediatric Use Marketing Authorization in Europe. The company has reported strong product sales growth in 2025, driven by an enhanced go-to-market approach, expanding patient support programs, and increased awareness of cisplatin-induced ototoxicity prevention. Additionally, Fennec strengthened its patent portfolio with a 2025 U.S. patent issuance covering the pharmaceutical composition of sodium thiosulfate. Fennec Pharmaceuticals employs a focused commercial strategy with a specialized sales force targeting pediatric oncology specialists and cooperation with specialty distributors to maximize patient access. It continues to invest in clinical research, commercialization expansion, and intellectual property protection to solidify its market position as a leader in preventing chemotherapy-induced hearing loss in young cancer patients. The company is publicly traded under the ticker FENC on NASDAQ and TSX. This comprehensive profile reflects Fennec Pharmaceuticals Inc.’s offerings, recent strategic licensing and regulatory achievements, clinical development progress, and commercial execution in its niche therapeutic area.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Announces Results of Annual Meeting
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
FENC Secures Second Consecutive Inclusion in S&P Global Dow Jones Best in Class Emerging Markets Index
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of “Moderate Buy” from Brokerages
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adherex Technologies (FENC) to Release Earnings on Wednesday
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update